Hidefumi Kinoshita

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.

David F. Jarrard, Hidefumi Kinoshita, Yan Shi et al. · PubMed · 1998 · 236 citations

Life Sciences, Genetics, Oncology +17

Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer.

Hidefumi Kinoshita, Y. Shi, Carol Sandefur et al. · PubMed · 2000 · 188 citations

Medicine, Molecular Biology, Oncology +17

Formation of 8‐hydroxy‐2′‐deoxyguanosine and 4‐hydroxy‐2‐nonenal‐modified proteins in human renal‐cell carcinoma

Keisei Okamoto, Shinya Toyokuni, Kôji Uchida et al. · International Journal of Cancer · 1994 · 179 citations

Medicine, Cancer Biology, Oncology +17

Antiandrogen Bicalutamide Promotes Tumor Growth in a Novel Androgen-Dependent Prostate Cancer Xenograft Model Derived from a Bicalutamide-Treated Patient

Toru Yoshida, Hidefumi Kinoshita, Takehiko Segawa et al. · Cancer Research · 2005 · 178 citations · Full text

Medicine, Oncology, Pharmacology +15